Stock in Focus: Pharma company Panacea Biotech has received an important update in its ongoing vaccine supply contract with UNICEF. This contract is related to the supply of pre-qualified pentavalent vaccine Easyfive-TT (DTwP-HepB-Hib) from WHO, whose period is from 2023 to 2027.
Contract value increased for 2026 and 2027
According to Panacea Biotech, the value of the contract for the year 2026 has increased by $2.55 million to $16.8 million. This is approximately Rs 23 crore in Indian currency. At the same time, the contract value for 2027 has increased by $ 2.70 million i.e. approximately Rs 24 crore. Now it has reached $15.18 million.
New order also received for 2027
Apart from this, Panacea Biotech has also received a new award for 2027. Its value is 3.68 million dollars i.e. about Rs 33 crore. With this, order visibility for the coming years seems to be getting stronger.
Long term agreement for polio vaccine
Earlier in October, UNICEF had also given a big order to the company for polio vaccine. Panacea Biotech has received this letter of award under a long term agreement. According to this, the company will supply bOPV vaccine to the UN agency from 1 April 2026 to 31 March 2030. This supply will be made in 10 and 20 vial presentations.
share price situation
Shares of Panacea Biotech closed at Rs 359.50, up 0.93 per cent, on the NSE on December 24. The stock has fallen 13.64% in the last 6 months. At the same time, it has come down by 17.02% in 1 year. Its market cap is Rs 2.20 thousand crore.
Business of Panacea Biotech
Panacea Biotech’s business focuses on research, manufacturing and global supply of vaccines, pharmaceutical formulations and biologics. The company specifically manufactures pentavalent, polio and other public health related vaccines, which are supplied to UNICEF and other international agencies through WHO pre-qualification.
Apart from this, Panacea Biotech also focuses on generic medicines, branded formulations and healthcare solutions, where the company works on government and institutional orders in India as well as international markets.
Disclaimer: The information provided here is being given for information only. It is important to mention here that investing in the market is subject to market risks. As an investor, always consult an expert before investing money. Moneycontrol never advises anyone to invest money here.